CRVS
Corvus Pharmaceuticals, Inc.
$11.93
+2.84%
$1.0B
No data for this timeframe.
Vol
Market Cap$1.0B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (92%)
Inst. Holders50 funds
Inst. Value$432.7M
Inst. Activity14 buys / 2 sells
Insider Activity1B / 0S
Insider Net $$60.3K
SEC Reports4
Press Releases3
Recent Activity
Jun 11, 2026
SEC
An institutional cluster formed in CRVS during 2025-Q3, with five institutions — including State Street, Fidelity, and W
INST-CLUSTER — Impact 3/10
Jun 9, 2026
other
Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China
$13.5 million financing, including $5 million from Corvus, supports ongoing generation of soquelitin
May 18, 2026
Insider
MILLER RICHARD A MD bought 5,000 shares
President and CEO @ $12.05 ($60.3K)
May 14, 2026
SEC
Corvus Pharmaceuticals presented final Phase 1 data for soquelitinib in atopic dermatitis at the SID Annual Meeting, sho
8-K — Impact 7/10
May 7, 2026
SEC
Corvus Pharmaceuticals reported Q1 2026 net loss of $13.7M ($0.15/share), slightly missing consensus of $0.14 loss. The
8-K — Impact 4/10
Apr 23, 2026
Insider
Chan Andrew C. was granted 30,000 shares
Director
Jan 28, 2026
Insider
Thompson Peter A. acquired via exercise 30,000 shares
Director @ $15.00 ($450.0K)
Inst.
STATE STREET CORP — ADD
3,565,992 shares ($52.2M)
Price Targets
$33.33
+179.4% upside
Strong Buy
Current $11.93
Low $27.00
Median $31.50
High $42.00
6 analysts
$27.00
$42.00
Analyst Ratings
4Strong Buy
8Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 17, 2026 | Goldman Sachs | INITIATE | Buy |
| Mar 13, 2026 | Oppenheimer | REITERATE | Outperform → Outperform |
| Jan 22, 2026 | Jefferies | MAINTAIN | Buy → Buy |
| Jan 21, 2026 | Oppenheimer | MAINTAIN | Outperform → Outperform |
| Jan 21, 2026 | Barclays | MAINTAIN | Overweight → Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.17 ▲ +1.4% | $-0.20 — $-0.15 | -32% YoY | 3 |
| Next Q | $-0.19 ▲ +3.8% | $-0.22 — $-0.17 | -58% YoY | 3 |
| Current FY | $-0.72 ▲ +4.1% | $-0.80 — $-0.65 | -33% YoY | 3 |
| Next FY | $-0.95 ▼ -12.4% | $-1.12 — $-0.86 | -32% YoY | 3 |
Latest Reports
NEUTRAL
INST-CLUSTER
3/10
An institutional cluster formed in CRVS during 2025-Q3, with five institutions — including State Street, Fidelity, and W
Jun 11, 2026
BULLISH
8-K
7/10
Corvus Pharmaceuticals presented final Phase 1 data for soquelitinib in atopic dermatitis at the SID Annual Meeting, sho
May 14, 2026
NEUTRAL
Press
4/10
Corvus Pharmaceuticals will host an investor meeting on May 14, 2026, to highlight new Phase 1 clinical data for soqueli
Apr 21, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BlackRock, Inc. | $90.1M | — |
| STATE STREET CORP | $52.2M | ADD |
| VANGUARD CAPITAL MANAGEMENT LLC | $47.3M | — |
| MORGAN STANLEY | $36.6M | TRIM |
| WELLINGTON MANAGEMENT GROUP LLP | $33.9M | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 18, 2026 | MILLER RICHARD | BUY | $60.3K |
| Apr 23, 2026 | Chan Andrew | A | $0.00 |
| Jan 28, 2026 | Thompson Peter | M | $450.0K |
50 institutional holders with $432.7M total value (29,607,047 shares) as of 2026-Q1. Top holders: BlackRock,, STATE, VANGUARD. Net buying activity: 14 institutions added/increased vs 2 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 6,160,422 | $90.1M | 20.8% | — |
| 2 | STATE STREET CORP | 3,565,992 | $52.2M | 12.1% | ADD +27.9% |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 3,234,538 | $47.3M | 10.9% | — |
| 4 | MORGAN STANLEY | 2,498,825 | $36.6M | 8.4% | TRIM -30.0% |
| 5 | WELLINGTON MANAGEMENT GROUP LLP | 2,318,517 | $33.9M | 7.8% | DOUBLED +636.8% |
| 6 | GOLDMAN SACHS GROUP INC | 1,540,809 | $22.5M | 5.2% | — |
| 7 | Hood River Capital Management LLC | 1,335,109 | $19.5M | 4.5% | NEW |
| 8 | Polar Capital Holdings Plc | 1,070,174 | $15.7M | 3.6% | NEW |
| 9 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 750,000 | $11.0M | 2.5% | NEW |
| 10 | VANGUARD PORTFOLIO MANAGEMENT LLC | 669,895 | $9.8M | 2.3% | — |
| 11 | MARSHALL WACE, LLP | 548,285 | $8.0M | 1.9% | DOUBLED +153.5% |
| 12 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 543,400 | $7.9M | 1.8% | — |
| 13 | TWO SIGMA INVESTMENTS, LP | 539,869 | $7.9M | 1.8% | TRIM -29.4% |
| 14 | VANGUARD FIDUCIARY TRUST CO | 504,631 | $7.4M | 1.7% | — |
| 15 | RA CAPITAL MANAGEMENT, L.P. | 450,000 | $6.6M | 1.5% | — |
| 16 | CITADEL ADVISORS LLC | 442,522 | $6.5M | 1.5% | — |
| 17 | VOLORIDGE INVESTMENT MANAGEMENT, LLC | 278,007 | $4.1M | 0.9% | — |
| 18 | CITADEL ADVISORS LLC | 267,800 | $3.9M | 0.9% | — |
| 19 | BARCLAYS PLC | 243,776 | $3.6M | 0.8% | DOUBLED +312.7% |
| 20 | BANK OF AMERICA CORP /DE/ | 237,004 | $3.5M | 0.8% | ADD +55.6% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| STATE STREET CORP | ADD | 2,788,223 | 3,565,992 | +27.9% | $52.2M | 2026-Q1 |
| MORGAN STANLEY | TRIM | 3,567,908 | 2,498,825 | -30.0% | $36.6M | 2026-Q1 |
| WELLINGTON MANAGEMENT GROUP LLP | DOUBLED | 314,683 | 2,318,517 | +636.8% | $33.9M | 2026-Q1 |
| Hood River Capital Management LLC | NEW | — | 1,335,109 | — | $19.5M | 2026-Q1 |
| Polar Capital Holdings Plc | NEW | — | 1,070,174 | — | $15.7M | 2026-Q1 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | NEW | — | 750,000 | — | $11.0M | 2026-Q1 |
| MARSHALL WACE, LLP | DOUBLED | 216,248 | 548,285 | +153.5% | $8.0M | 2026-Q1 |
| Nuveen, LLC | DOUBLED | 68,064 | 149,126 | +119.1% | $2.2M | 2026-Q1 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | DOUBLED | 17,497 | 101,779 | +481.7% | $1.5M | 2026-Q1 |
| VOYA INVESTMENT MANAGEMENT LLC | DOUBLED | 27,661 | 99,631 | +260.2% | $1.5M | 2026-Q1 |
| Connor, Clark & Lunn Investment Management Ltd. | DOUBLED | 28,117 | 83,907 | +198.4% | $1.2M | 2026-Q1 |
| FMR LLC | ADD | 2,291 | 3,561 | +55.4% | $52.1K | 2026-Q1 |
| PRICE T ROWE ASSOCIATES INC /MD/ | DOUBLED | 34,105 | 2,917,300 | +8453.9% | $42.7K | 2026-Q1 |
| CWM, LLC | DOUBLED | 205 | 1,237 | +503.4% | $18.1K | 2026-Q1 |
| Allworth Financial LP | DOUBLED | 17 | 62 | +264.7% | $908.00 | 2026-Q1 |
| Point72 Asset Management, L.P. | EXIT | 2,875,000 | 0 | -100.0% | $0.00 | 2026-Q1 |
| MORGAN STANLEY | DOUBLED | 617,224 | 3,567,908 | +478.1% | $27.5M | 2025-Q4 |
| Point72 Asset Management, L.P. | TRIM | 6,454,274 | 2,875,000 | -55.5% | $22.1M | 2025-Q4 |
| STATE STREET CORP | DOUBLED | 1,006,319 | 2,788,223 | +177.1% | $21.5M | 2025-Q4 |
| RTW INVESTMENTS, LP | NEAR_EXIT | 2,679,479 | 447,607 | -83.3% | $3.4M | 2025-Q4 |
| WELLINGTON MANAGEMENT GROUP LLP | ADD | 180,175 | 314,683 | +74.7% | $2.4M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 151,966 | 236,495 | +55.6% | $1.8M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 203,360 | 143,598 | -29.4% | $1.1M | 2025-Q4 |
| NEOS Investment Management LLC | ADD | 59,202 | 80,893 | +36.6% | $622.9K | 2025-Q4 |
| D. E. Shaw & Co., Inc. | DOUBLED | 25,575 | 64,915 | +153.8% | $499.8K | 2025-Q4 |
3 unique insiders with 3 transactions. Net insider value: $60.3K ($60.3K bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 18, 2026 | MILLER RICHARD A MD | President and CEO | BUY | 5,000 | $12.05 | $60.3K |
| Apr 23, 2026 | Chan Andrew C. | Director | AWARD | 30,000 | — | — |
| Jan 28, 2026 | Thompson Peter A. | Director | EXERCISE | 30,000 | $15.00 | $450.0K |
4 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 3 neutral. Avg impact: 4.5/10.
NEUTRAL
INST-CLUSTER
3/10
An institutional cluster formed in CRVS during 2025-Q3, with five institutions — including State Str
Jun 11, 2026
BULLISH
8-K
7/10
Corvus Pharmaceuticals presented final Phase 1 data for soquelitinib in atopic dermatitis at the SID
May 14, 2026
NEUTRAL
8-K
4/10
Corvus Pharmaceuticals reported Q1 2026 net loss of $13.7M ($0.15/share), slightly missing consensus
May 7, 2026
NEUTRAL
DEFA14A
4/10
Corvus Pharmaceuticals filed a definitive proxy statement (DEFA14A) for its 2026 Annual Meeting, whi
Apr 24, 2026
NEUTRAL
4/10
Corvus Pharmaceuticals will host an investor meeting on May 14, 2026, to highlight new Phase 1 clini
Apr 21, 2026
BULLISH
8/10
Corvus Pharmaceuticals reported financial results for Q4 and full year 2025, highlighted by positive
Mar 12, 2026
NEUTRAL
3/10
Corvus Pharmaceuticals announced plans to host a conference call on March 12, 2026, to discuss its f
Mar 5, 2026
Current analyst consensus: Strong Buy (92% buy). Based on 13 analysts: 4 strong buy, 8 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$33.33 mean target
+179.4% upside
Strong Buy (1.14)
$27.00 Low
$42.00 High
| Metric | Value |
|---|---|
| Current Price | $11.93 |
| Target Low | $27.00 |
| Target Mean | $33.33 |
| Target Median | $31.50 |
| Target High | $42.00 |
| # Analysts | 6 |
| Recommendation | Strong Buy (1.14) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.17 | $-0.20 | $-0.15 | -32.1% | +1.4% | 0↑ 3↓ | $0.0B | 0.0% | 3 |
| Next Q 2026-09-30 |
$-0.19 | $-0.22 | $-0.17 | -58.3% | +3.8% | 0↑ 3↓ | $0.0B | 0.0% | 3 |
| Current FY 2026-12-31 |
$-0.72 | $-0.80 | $-0.65 | -33.4% | +4.1% | 0↑ 3↓ | $0.0B | 0.0% | 3 |
| Next FY 2027-12-31 |
$-0.95 | $-1.12 | $-0.86 | -32.1% | -12.4% | 0↑ 3↓ | $0.0B | 0.0% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.170 | |
| 7d ago | $-0.163 | -0.007 |
| 30d ago | $-0.172 | +0.002 |
| 60d ago | $-0.160 | -0.010 |
| 90d ago | $-0.147 | -0.023 |
5 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 17, 2026 | Goldman Sachs | INITIATE | — | Buy |
| Mar 13, 2026 | Oppenheimer | REITERATE | Outperform | Outperform |
| Jan 22, 2026 | Jefferies | MAINTAIN | Buy | Buy |
| Jan 21, 2026 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| Jan 21, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Jan 20, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 8 | 1 | 0 | 0 | 92% | |
| May 1, 2026 | 4 | 8 | 1 | 0 | 0 | 92% | |
| Apr 1, 2026 | 5 | 7 | 1 | 0 | 0 | 92% | |
| Mar 1, 2026 | 5 | 7 | 1 | 0 | 0 | 92% | |
| Feb 1, 2026 | 5 | 7 | 1 | 0 | 0 | 92% | |
| Jan 1, 2026 | 5 | 7 | 1 | 0 | 0 | 92% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 9, 2026
other
Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China
$13.5 million financing, including $5 million from Corvus, supports ongoing generation of soquelitinib clinical data in China for atopic dermatitis an
Jun 9, 2026
short_volume
Short Volume: CRVS — 55.3% short (0.4M / 0.6M)
Short: 353,099 | Exempt: 15,094 | TRF Vol: 638,428 | Short Ratio: 55.3% | Off-exchange volume (dark pool + OTC)
May 20, 2026
other
Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference
<p>SOUTH SAN FRANCISCO, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical com
May 14, 2026
short_volume
Short Volume: CRVS — 56.9% short (1.1M / 1.9M)
Short: 1,097,320 | Exempt: 75,958 | TRF Vol: 1,929,222 | Short Ratio: 56.9% | Off-exchange volume (dark pool + OTC)
May 7, 2026
earnings
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results
<p align="center"><em>Soquelitinib clinical development for atopic dermatitis advancing with Phase 1 cohort 4 positive data and initiation of Phase 2
May 7, 2026
earnings_calendar
CRVS Q1 2026 Earnings Scheduled — 2026-05-07
Apr 29, 2026
short_volume
Short Volume: CRVS — 70.6% short (0.7M / 1.0M)
Short: 711,763 | Exempt: 0 | TRF Vol: 1,008,676 | Short Ratio: 70.6% | Off-exchange volume (dark pool + OTC)
Apr 24, 2026
short_volume
Short Volume: CRVS — 59.1% short (0.3M / 0.5M)
Short: 300,276 | Exempt: 35,567 | TRF Vol: 507,978 | Short Ratio: 59.1% | Off-exchange volume (dark pool + OTC)
Apr 23, 2026
other
Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of Directors
<p>SOUTH SAN FRANCISCO, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical c
Apr 23, 2026
short_volume
Short Volume: CRVS — 74.7% short (0.7M / 0.9M)
Short: 690,256 | Exempt: 15,470 | TRF Vol: 923,445 | Short Ratio: 74.7% | Off-exchange volume (dark pool + OTC)
Apr 22, 2026
short_volume
Short Volume: CRVS — 63.5% short (0.7M / 1.1M)
Short: 723,734 | Exempt: 700 | TRF Vol: 1,140,412 | Short Ratio: 63.5% | Off-exchange volume (dark pool + OTC)
Apr 21, 2026
fda
Corvus Pharmaceuticals to Host Investor and Analyst Meeting on May 14, 2026 to Highlight Soquelitinib Data Being Presented at the Society for Investigative Dermatology (SID) Annual Meeting
<p align="center"><em>Two oral presentations including late-breaker at SID </em></p>
Apr 21, 2026
short_volume
Short Volume: CRVS — 62.1% short (0.4M / 0.7M)
Short: 405,333 | Exempt: 0 | TRF Vol: 652,817 | Short Ratio: 62.1% | Off-exchange volume (dark pool + OTC)
Apr 17, 2026
short_volume
Short Volume: CRVS — 78.7% short (0.9M / 1.1M)
Short: 852,706 | Exempt: 900 | TRF Vol: 1,083,850 | Short Ratio: 78.7% | Off-exchange volume (dark pool + OTC)
Mar 27, 2026
short_volume
Short Volume: CRVS — 79.4% short (0.4M / 0.5M)
Short: 404,891 | Exempt: 0 | TRF Vol: 509,671 | Short Ratio: 79.4% | Off-exchange volume (dark pool + OTC)